Patients taking Kerendia saw significant reduction in cardiovascular death and hospitalization and urgent visits for heart ...

The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.

The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.

Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...

Heart failure with preserved ejection fraction (HFpEF) – a condition in which the heart pumps normally but still fails to meet the body's needs – is affecting an increasing number of people, ...

The US Food and Drug Administration (FDA) has granted 510(k) clearance for Tempus AI’s ECG-Low (ejection fraction) EF ...

Finerenone gained FDA approval for heart failure treatment, showcasing significant benefits in reducing cardiovascular events ...

The US regulator has cleared use of Kerendia (finerenone) for the treatment of heart failure patients who have a left ...

Tempus AI, Inc. (NASDAQ:TEM) saw its stock rise 3% on Wednesday following the announcement that the company obtained 510(k) ...

The use of SGLT2 inhibitors has been a game-changer in the treatment of heart failure (HF). Now, another drug class has ...

A 74-year-old woman develops haemolytic anaemia and stress cardiomyopathy after a tick bite, highlighting a rare cardiac complication of babesiosis.

The era of predictive modeling enhanced with machine learning and artificial intelligence (AI) to aid clinical ...